{"name":"Shenzhen TargetRx Co., Ltd.","slug":"shenzhen-targetrx-co-ltd","ticker":"","exchange":"","domain":"shenzhentargetrx.com","description":"","hq":"Guangdong","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"TGRX-326","genericName":"TGRX-326","slug":"tgrx-326","indication":"Type 2 diabetes","status":"phase_3"},{"name":"TGRX-678","genericName":"TGRX-678","slug":"tgrx-678","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"cycle 1: treatment drug","genericName":"cycle 1: treatment drug","slug":"cycle-1-treatment-drug","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"TKI","genericName":"TKI","slug":"tki","indication":"Chronic myeloid leukemia","status":"phase_3"}]}],"pipeline":[{"name":"cycle 1: treatment drug","genericName":"cycle 1: treatment drug","slug":"cycle-1-treatment-drug","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TGRX-326","genericName":"TGRX-326","slug":"tgrx-326","phase":"phase_3","mechanism":"TGRX-326 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TGRX-678","genericName":"TGRX-678","slug":"tgrx-678","phase":"phase_3","mechanism":"TGRX-678 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TKI","genericName":"TKI","slug":"tki","phase":"phase_3","mechanism":"TKI inhibits tyrosine kinases to block cancer cell proliferation and survival.","indications":["Chronic myeloid leukemia","Non-small cell lung cancer","Gastrointestinal stromal tumor"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNdERjZktGNGhyZlc4bGVGd2Nhck9wTmpwakVRcHBDMGtpR0lMMjlDSXFnYkMybmJTRklxb1liQ21qWTBIMTFOVlBPVzRPaDRQRW1wT2loWXY1UHBGdklEZ0hNbDU2Q3FsQnktSWlVZ2pzTy1FMXdma09JeUdYNWJLNHZUQ2VXYzh5YXVnNHpuZTV3ZGRrTmtCMXdyOEFQZjhXeWIzSml1dXdlV25OV2pkVVlkVm1TaGpNd2NBenRn?oc=5","date":"2026-03-25","type":"deal","source":"Seeking Alpha","summary":"Merck's Deal For Terns And Its Stellar CML Drug Candidate Looks Like Good Business (MRK) - Seeking Alpha","headline":"Merck's Deal For Terns And Its Stellar CML Drug Candidate Looks Like Good Business (MRK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQWEhwcjFTVEI5WUFRU01KNnd3MWluTDlubzhPMzlCLVViSUF5LVFSRUpNYnFrSEZkWEhoMEJxcDJjSlVTcDlYSDlIaFhCRklBSGE2dUp5eDRCZXpMSWFFLWI1bVc4Y2FLUm9YaGRjYTdXbDVyY1NjZFdKYVk0ZzU0bkVieWFEemhtVXFROHVGQVV0UWgtV2lrdTZqbWhNNHRKZ2c?oc=5","date":"2025-12-09","type":"trial","source":"Seeking Alpha","summary":"Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again (NASDAQ:TERN) - Seeking Alpha","headline":"Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again (NASDAQ:TERN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE56VGFhU2VMeFpPV0xhWDhwUERySmtjMEc1VXl1aEhKZ2FZSktjRVFPWVMyUG5MbE4wdm5MTWU1RG4tT2dVclpscmQ5X1laNVhpN2YwVVBYNUVJbzUxZWc?oc=5","date":"2025-01-28","type":"pipeline","source":"The Pharma Letter","summary":"Shenzhen TargetRx - The Pharma Letter","headline":"Shenzhen TargetRx","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNa3BRWGlWM2VQVkl5QnhURzFLbUVkLXJfbUZTa3ZlYmFUSlVEMkR1V2hKMFNDbFcxekY4ZUNPSk9zSHNNQW9CVE9IaFFxNDVjOXh1NVBBZ2R6MFBxUVo0eE5wbVh2MDMtZXNKV000WW5DUFc4UzBwci1KVUgtLW5KMHNUdkZqZi0yTTNJakNxZU82X3RaaUE?oc=5","date":"2025-01-23","type":"pipeline","source":"The Pharma Letter","summary":"Shenzhen TargetRx raises $50 million for bold cancer mission - The Pharma Letter","headline":"Shenzhen TargetRx raises $50 million for bold cancer mission","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxOLTNGclp3R1k1Ql95djVkdTRCRG1mbmlmSDhFTm52MlJGZjdaNG9qU1VfbWxyUUVoOWs3aUJvUUY2M3o4bEtfUExtVXNOY1F0MUU3MzRWbFRSYmZMb0V2eEJuUnNTU1cxQUVFbXZieW1TQmxXRWxuUDRtZlM2allWeUpNQlVvN0gyNHNaSE9CTjQ0TE84ZTJJT0tlSlQtX0FCQWNqMXdhMElMa1lRdDgtZDRRNU84U1otT2ZCbXdEekttb3FKSFNZbnIxRndueUw4S0d4OTR5V3BpNkV0dTNTRzVMM2oxVGxrd1p3TFZCZmNpdXIyZGJkWm1xOW83aDM0UFV2WUM3cTdWOHVrUDg2VHJqcC1YNmxmbWl4VmlhNjlKYkZHMXc?oc=5","date":"2024-11-11","type":"trial","source":"PR Newswire","summary":"NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeuti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOTWFlc3lEVzYtMnk5blA3RzB0anVGVS1vb2hlbDlKWjdzTTBWM09RZjVBREoxem1tRGd1SkFhVWRmYkdldnFRSURtbnpuaVFscl9GZlZ4d2tRblU5NEx5Y1Bqc2pCcWtaSDVsNzRVQ0lBVUE4dDFweHFhdnNqZHZDVGZiVGU3SDU3bmp6WHZjMnRBTnFhTC1xSENlendBSUZ0NDg3Mk92SFN2bkJNMUFuVnQxWDlacDU1MWZMVQ?oc=5","date":"2024-09-03","type":"deal","source":"Contract Pharma","summary":"Simcere Zaiming, TargetRx Enter Collaboration Agreement Focused on TGRX-326 - Contract Pharma","headline":"Simcere Zaiming, TargetRx Enter Collaboration Agreement Focused on TGRX-326","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPT3ctSUhsLWpYcHlzTkxYT2hMMnp4S3VJNHZNVTIzSEtMSG8xeWtQSU9Rd3JLd011Vlg1NTZ6NjlfaUdNeHhZdE1JbjlFZEx6UnR2dF95dldVX1ZrcFdqVnZZTE9mcXJUM2xtSU5XbkdTN20tdk96cldFYmZFSXNjV2pSaUFlMXJYU3pHOVZWdHBrY2l4bi1ibTVFRms2ajE4emlwcTY1dDJic1hCYnNBZUtLVEl4OGVUUXdFUFhrWGd3Z2s2MWVoQ2JOeUdJU0NkLWc5enpVYmJtdW5KVlBnWUJISXVSdzUyT0tIb0dn?oc=5","date":"2024-08-30","type":"pipeline","source":"PR Newswire","summary":"ALK Inhibitors Market: A Comprehensive Overview of Current Trends and Future Projections | DelveInsight - PR Newswire","headline":"ALK Inhibitors Market: A Comprehensive Overview of Current Trends and Future Projections | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":1,"phase_3":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}